- $106.64m
- $100.07m
U.S. STOCKS ON THE MOVE-PACCAR, Cullinan Oncology, 3M, Peloton
U.S. STOCKS ON THE MOVE-HighPeak Energy , CymaBay Therapeutics, Polypid
Polypid surges on regulatory pathway for infection treatment
Brief: PolyPid Gives Positive Update For D-PLEX₁₀₀ For Prevention Of Surgical Site Infections
Brief: PolyPid Announces Publication Of Phase 2 Clinical Trial Post-HOC Analysis For D-Plex₁₀₀
Brief: Polypid Announces Scheduling Of Type D Meeting With U.S. FDA
Brief: PolyPid Announces Receipt Of Nasdaq Minimum Bid Price Notification
PolyPid Ltd reports results for the quarter ended in September - Earnings Summary
PolyPid Ltd expected to post a loss of 54 cents a share - Earnings Preview
Polypid rises on cost-reduction plan to extend cash runway
Brief: Polypid Announces Cost Reduction Plan
Brief: PolyPid Announces Eligibility For European Medicines Agency Centralized Procedure For D-Plex₁₀₀ For The Prevention Of Surgical Site Infections In Abdominal Surgery
Brief: Polypid Announces Mid-Stage Study Results For D-Plex₁₀₀
Brief: Polypid Announces Presentation Of Phase 2 D-Plex₁₀₀ Clinical Data At The European Society For Coloproctology Scientific Conference
U.S. STOCKS ON THE MOVE-Kohl, Okta, Nano Labs
U.S. STOCKS ON THE MOVE-Farmer Bros, gold miners, U.S. banks
Polypid hits record low after surgery infection treatment study fails
Brief: PolyPid Announces Top-Line Results Of Phase 3 Shield I Trial Of D-Plex₁₀₀ For Prevention Of Surgical Site Infections In Abdominal Surgery
Polypid tanks after surgery infection treatment study fails